<DOC>
	<DOCNO>NCT01552356</DOCNO>
	<brief_summary>This phase I trial study side effect best dose pazopanib hydrochloride treat patient solid tumor spread place body usually cure controlled treatment ( advanced ) respond treatment ( refractory ) . Pazopanib hydrochloride may prevent growth new blood vessel tumor need grow . Studying sample blood laboratory patient receive pazopanib hydrochloride may help doctor learn effect body drug . It may also help doctor understand well patient respond treatment .</brief_summary>
	<brief_title>Pazopanib Hydrochloride Treating Patients With Advanced Refractory Solid Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To assess feasibility safety individualize pazopanib ( pazopanib hydrochloride ) monotherapy base upon attained pazopanib plasma concentration achieve desire target pazopanib plasma concentration high possible fraction treat patient . SECONDARY OBJECTIVES : I . To assess whether patient cytochrome P450 ( CYP ) polymorphism may correlate attain pazopanib level response standard pazopanib dosing . II . To assess whether patient trough pazopanib level attain 24 hour initiation 800 mg daily fasting may predict steady state trough pazopanib level 14 day pazopanib administration . III . To assess whether patient trough pazopanib level may correlate observed pazopanib toxicity . OUTLINE : This dose-escalation study . Patients receive pazopanib hydrochloride orally ( PO ) daily ( QD ) day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Course length extend 56 day discretion treat physician 12 course ( 1 year ) treatment study . After completion study treatment , patient follow 3 month .</detailed_description>
	<criteria>Histologic proof cancer amenable alternative curative clearly superior standard treatment option Measurable disease Hemoglobin ( Hgb ) &gt; = 8.0 g/dL Absolute neutrophil count ( ANC ) &gt; = 1,500/uL Platelet ( PLT ) = 100,000/uL Activated partial thromboplastin time ( APTT ) &lt; 1.2 time upper limit normal ( ULN ) ; ( Note : use warfarin prohibit ; low molecular weight heparin allow , long criterion meet ) International normalize ratio ( INR ) &lt; 1.2 time ULN ; ( Note : use warfarin prohibit ; low molecular weight heparin allow , long criterion meet ) Direct bilirubin = &lt; 1.5 X upper limit normal ( ULN ) ( subject Gilbert 's syndrome elevation indirect bilirubin eligible ) Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) = &lt; 2.5 X ULN Creatinine = &lt; 1.5 time ULN OR measure creatinine clearance &gt; = 60 mL/min 1.73 m^2 Urine protein/creatinine ratio &lt; 1 24hour urine &lt; 1 gram &lt; Grade 2 hypo/hyperkalemia &lt; Grade 3 hypo/hypercalcemia &lt; Grade 3 hypo/hyperphosphatemia &lt; Grade 3 hypo/hypermagnesemia Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 1 Ability provide inform consent Willing return Mayo Clinic follow Life expectancy &gt; = 84 day ( 3 month ) Willingness provide mandatory blood sample pazopanib drug level assessment require dosage adjustment , well required pharmacogenomic study Women childbearing potential : negative serum pregnancy test do = &lt; 14 day prior registration Known standard therapy patient 's disease potentially curative definitely capable extend life expectancy Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Corrected QT interval ( QTc ) &gt; = 480 msec and/or receive concomitant medication associate risk QTc prolongation and/or torsades de pointes ; NOTE : medication discontinue replace drug carry risk Subjects follow cardiovascular condition within past 6 month Cerebrovascular accident ( CVA ) transient ischemic attack ( TIA ) Admission unstable angina Myocardial infarction Cardiac angioplasty stenting Coronary artery bypass graft surgery Pulmonary embolism , untreated deep venous thrombosis ( DVT ) DVT treat therapeutic anticoagulation le 6 week Arterial thrombosis Symptomatic peripheral vascular disease Class III IV heart failure define New York Heart Association ( NYHA ) functional classification system ; subject history class II heart failure asymptomatic treatment may consider eligible Active cardiac arrhythmia ( except sinus arrhythmia , atrial fibrillation , asymptomatic premature ventricular contraction [ PVCs ] ) Ejection fraction &lt; institutional low limit normal ( LLN ) and/or history cardiomyopathy Receiving medication know risk torsades de pointes ; follow medication specifically prohibit : amiodarone , arsenic trioxide , bepridil , chloroquine , chlorpromazine , cisapride , clarithromycin , disopyramide , dofetilide , dolasetron , droperidol , erythromycin , halofantrine , haloperidol , ibutilide levomethadyl , mesoridazine , methadone , pentamidine , pimozide , procainamide , quinidine , sotalol , sparfloxacin , thioridazine ; patient watch carefully indication torsades de pointes , syncope ; perform additional electrocardiogram ( EKGs ) subject must take one medication require ; however , additional investigation , include EKGs , may perform per treat physician 's judgment Blood pressure ( BP ) &gt; 140 mmHg ( systolic ) &gt; 90 mmHg ( diastolic ) ; initiation adjustment BP medication permit prior registration provide average three BP reading visit prior registration &lt; 140/90 mmHg Any follow prior therapy : Chemotherapy = &lt; 28 day prior registration Mitomycin C/nitrosoureas = &lt; 42 day prior registration Immunotherapy = &lt; 28 day prior registration Biologic therapy = &lt; 28 day prior registration Radiation therapy = &lt; 28 day prior registration Radiation &gt; 25 % bone marrow Failure fully recover acute , reversible effect prior chemotherapy ( antineoplastic therapy ) radiation therapy Subjects know brain metastases Any following : Pregnant woman Nursing woman Men woman childbearing potential unwilling employ adequate contraception Other concurrent chemotherapy , immunotherapy , radiotherapy , ancillary therapy consider investigational ( utilized nonFood Drug Administration [ FDA ] approve indication context research investigation ) ; Note : concomitant use zoledronic acid , pamidronate denosumab allow ( initiated patient study therapy investigator discretion ) Comorbid systemic illness severe concurrent disease , judgment investigator , would make patient inappropriate entry study interfere significantly proper assessment safety toxicity prescribe regimen Immunocompromised patient ( relate use corticosteroid ) include patient know human immunodeficiency virus ( HIV ) positive cluster differentiation ( CD ) 4 count &lt; 200 Receiving investigational agent Other active malignancy = &lt; 3 year prior registration ; EXCEPTIONS : nonmelanotic skin cancer carcinomainsitu cervix ; NOTE : history prior malignancy , must receive specific treatment ( e.g . hormonal chemotherapy ) cancer Prior use pazopanib ( prior use kinase inhibitor allow ) Receiving medication substance strong moderate inhibitor cytochrome P450 , family 3 , subfamily A , polypeptide 4 ( CYP3A4 ) ( indinavir , nelfinavir , atazanavir , ritonavir , clarithromycin , itraconazole , voriconazole , ketoconazole , nefazodone , saquinavir , telithromycin , aprepitant , erythromycin , fluconazole , grapefruit juice , verapamil , diltiazem ) ; use aforementioned strong moderate inhibitor prohibit &lt; 7 day prior registration Receiving medication substances inducer CYP3A4 ( efavirenz , nevirapine , carbamazepine , modafinil , phenobarbital , phenytoin , pioglitazone , rifabutin , rifampin , St. John 's wort ) ; use aforementioned inducer prohibit = &lt; 7 day prior registration Receiving mitotane within 6 month enrol study Subjects condition may impair ability swallow absorb oral medications/investigational product include : Any lesion , whether induced tumor , radiation condition , make difficult swallow capsule pill Prior surgical procedure affect absorption include , limited major resection stomach small bowel Active peptic ulcer disease Malabsorption syndrome Any follow condition : Serious nonhealing wound , ulcer , bone fracture Current use therapeutic warfarin ; Note : low molecular weight heparin allow ; prothrombin time ( PT ) /partial thromboplastin time ( PTT ) must meet inclusion criterion History bleed disorder , include patient afflict hemophilia , disseminate intravascular coagulation , abnormality coagulation potentially predispose patient bleed History hemoptysis excess 2.5 mL ( 1/2 teaspoon ) within 8 week prior first dose study drug Poorly control depression anxiety disorder , recent ( = &lt; 6 month ) suicidal ideation HIVpositive patient combination antiretroviral therapy ; appropriate study undertake patient receive combination antiretroviral therapy indicate Subjects condition may increase risk gastrointestinal bleed gastrointestinal perforation , include Active peptic ulcer disease Known intraluminal metastatic lesion Inflammatory bowel disease ( e.g. , ulcerative colitis , Crohn 's disease ) gastrointestinal condition increase risk perforation History abdominal fistula , gastrointestinal perforation intraabdominal abscess within 28 day prior begin study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>